Teva Pharmaceutical Industries (NYSE:TEVA) Releases Quarterly Earnings Results, Beats Expectations By $0.31 EPS

Teva Pharmaceutical Industries (NYSE:TEVA) issued its earnings results on Wednesday. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.31, FiscalAI reports. Teva Pharmaceutical Industries had a net margin of 4.24% and a return on equity of 46.13%. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter in the prior year, the firm posted $0.71 EPS. Teva Pharmaceutical Industries’s quarterly revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries updated its FY 2026 guidance to 2.570-2.770 EPS.

Here are the key takeaways from Teva Pharmaceutical Industries’ conference call:

• Management reported year-over-year growth in revenue and profitability, noting EBITDA up ~12%, EPS up ~19% and free cash flow improvement, which management says supports their pivot to an innovative biopharma model.
• The commercial portfolio is driving momentum—AUSTEDO, UZEDY and AJOVY delivered strong sales with AUSTEDO guidance of $2.4B–$2.55B and rapid uptake of AUSTEDO XR and UZEDY long‑acting injectable volumes cited as growth drivers.
• Several near‑term R&D catalysts are expected in 2026, including duvakitug maintenance data (H1), olanzapine LAI EU submission/anticipated approval, Anti‑IL‑15 vitiligo and celiac readouts, and completion of the DARI phase‑3 asthma study.
• Financial restructuring and efficiency progress — net debt reduced to about $13B (~2.5x EBITDA), $70M of transformation savings realized toward a $700M target by 2027, and management expects improving margins and deleveraging toward investment‑grade metrics.
• Management flagged near‑term headwinds and one‑offs: an expected ~ $1.1B generic Revlimid revenue decline in 2026, Q1 softness from Revlimid and AUSTEDO destocking/gross‑to‑net effects, and a Q4 impairment charge (~$773M) that weighed on GAAP results.

Teva Pharmaceutical Industries Trading Down 0.2%

NYSE:TEVA traded down $0.06 during trading hours on Wednesday, hitting $32.47. The company had a trading volume of 7,793,829 shares, compared to its average volume of 9,985,670. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 2.31. The company has a market cap of $37.24 billion, a P/E ratio of 54.41, a P/E/G ratio of 1.83 and a beta of 0.66. The company has a 50-day moving average of $29.94 and a 200 day moving average of $22.89. Teva Pharmaceutical Industries has a 1 year low of $12.47 and a 1 year high of $33.42.

Insider Activity at Teva Pharmaceutical Industries

In other news, CAO Amir Weiss sold 12,300 shares of the firm’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total value of $371,460.00. Following the sale, the chief accounting officer directly owned 5,650 shares in the company, valued at approximately $170,630. This trade represents a 68.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Roberto Mignone sold 200,000 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total value of $4,822,000.00. Following the sale, the director owned 495,000 shares of the company’s stock, valued at approximately $11,934,450. The trade was a 28.78% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 622,060 shares of company stock worth $17,076,965. 0.55% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several large investors have recently modified their holdings of the stock. CIBC Private Wealth Group LLC lifted its holdings in Teva Pharmaceutical Industries by 15.5% in the third quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company’s stock valued at $81,000 after acquiring an additional 540 shares during the period. CIBC Bancorp USA Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth $234,000. Danske Bank A S purchased a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth about $5,012,000. Advisory Services Network LLC lifted its stake in shares of Teva Pharmaceutical Industries by 11.1% in the third quarter. Advisory Services Network LLC now owns 53,055 shares of the company’s stock worth $1,072,000 after acquiring an additional 5,318 shares in the last quarter. Finally, NewEdge Advisors LLC grew its position in shares of Teva Pharmaceutical Industries by 5.2% in the 3rd quarter. NewEdge Advisors LLC now owns 44,150 shares of the company’s stock worth $892,000 after acquiring an additional 2,180 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 earnings beat: Teva reported $0.96 EPS vs. a $0.65 consensus and delivered +11.4% revenue growth year‑over‑year, signaling stronger operating leverage than expected. Earnings Press Release
• Positive Sentiment: Profit and revenue rise supported by branded‑drug sales and a milestone payment tied to initiating a late‑stage study for ulcerative colitis/Crohn’s disease — a near‑term cash and validation event for the pipeline. Reuters: Profit, revenue rise
• Positive Sentiment: Three consecutive years of growth: Teva reports 2025 revenue of $17.3B (+4% YoY) and highlights a pivot‑to‑growth strategy and pipeline catalysts that could support longer‑term valuation upside. GlobeNewswire: Growth release
• Neutral Sentiment: Analyst write‑ups: Zacks and other coverage provide metric‑level analysis of the quarter to help investors parse margin, ROE and segment trends versus estimates. Useful for modeling but not a driver on its own. Zacks: Q4 analysis
• Neutral Sentiment: Corporate PR/awareness: Teva launched a Huntington’s disease awareness campaign with Will Forte — positive for reputation and patient engagement but not an immediate financial catalyst. GlobeNewswire: Will Forte campaign
• Negative Sentiment: Mixed to cautious guidance: Management set FY‑2026 EPS at 2.570–2.770 (roughly in line with consensus) but issued revenue guidance of $16.4–16.8B below the ~$17.0B Street estimate — a potential limiter for upside until guidance visibility improves.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on TEVA. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Sunday, January 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. Barclays began coverage on Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They set an “overweight” rating and a $35.00 target price on the stock. Scotiabank assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 price objective for the company. Finally, The Goldman Sachs Group upped their price objective on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $33.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.